Skip to main content

TEVA PHARMACEUTICAL INDUSTRIES LTD

For the period ended Dec 31, 2023. Filed Feb 12, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 12, 2024

TEVA$42.97+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 16. Form 10-K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TEVA PHARMACEUTICAL INDUSTRIES LIMITED
By:/s/ Richard D. Francis
Name:Richard D. Francis
Title:President and Chief Executive Officer
Dated:February 12, 2024

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENT, that each of the undersigned directors and/or officers of Teva Pharmaceutical Industries Limited, a corporation organized under the laws of Israel, hereby constitutes and appoints Richard D. Francis, Eli Kalif, Dov Bergwerk and Amir Weiss, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign, execute and deliver with the U.S. Securities and Exchange Commission any and all amendments to this Annual Report on Form 10-K, with all exhibits thereto, and other documents in connection therewith, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this annual report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

NameTitleDate
By:/s/ Dr. Sol J. Barer Dr. Sol J. BarerChairman of the Board of DirectorsFebruary 12, 2024
By:/s/ Richard D. Francis Richard D. FrancisPresident and Chief Executive Officer and DirectorFebruary 12, 2024
By:/s/ Eli Kalif Eli KalifExecutive Vice President, Chief Financial Officer (Principal Financial Officer)February 12, 2024
By:/s/ Amir Weiss Amir WeissSenior Vice President, Chief Accounting Officer (Principal Accounting Officer)February 12, 2024
By:/s/ Rosemary A. Crane Rosemary A. CraneDirectorFebruary 12, 2024
By:/s/ Amir Elstein Amir ElsteinDirectorFebruary 12, 2024
NameTitleDate
By:/s/ Gerald M. Lieberman Gerald M. LiebermanDirectorFebruary 12, 2024
By:/s/ Roberto A. Mignone Roberto A. MignoneDirectorFebruary 12, 2024
By:/s/ Dr. Perry D. Nisen Dr. Perry D. NisenDirectorFebruary 12, 2024
By:/s/ Prof. Ronit Satchi-Fainaro Prof. Ronit Satchi-FainaroDirectorFebruary 12, 2024
By:/s/ Prof. Varda Shalev Prof. Varda ShalevDirectorFebruary 12, 2024
By:/s/ Janet S. Vergis Janet S. VergisDirectorFebruary 12, 2024
By:/s/ Dr. Tal Zaks Dr. Tal ZaksDirectorFebruary 12, 2024
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.